An observational study in Diffusion Tensor Imaging Prognosis and Brain Injury, Traumatic, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, none of them phase 3. Brain Injuries, Traumatic · Assistance Publique - Hôpitaux de Paris.
Among the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 15th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →6 of the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–50 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris
Ages 18+
By country, each count listing its studies:
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 220 is above the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.
Median enrollment 67 across the 8 interventional studies, 118 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04534777Assistance Publique - Hôpitaux de ParisMultimodal Neuroprognostication in Disorders of Consciousness | 2027-05 |
| NCT06146062Assistance Publique - Hôpitaux de ParisEffects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury. | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
With a mortality rate of over 13% in the neuro-intensive care unit, 86% of which are related to the withdrawal of active treatment, predicting a reliable neurological prognosis is of paramount importance in neuro-intensive care to help clinicians inform family members appropriately and tailor care to the patient's presumed wishes. This also helps justify aggressive resuscitation in patients with a presumed good prognosis and, conversely, avoid keeping patients with a poor neurological prognosis alive against their presumed wishes.
Current guidelines recommend multimodal neuro-prognostication, in which the clinician synthesizes prognostic data from the clinical examination, EEG, plasma or CSF biomarkers, and imaging to collaboratively develop an individualized prognosis, even though no study has evaluated the quality of this multimodal prognosis. Furthermore, existing variations depending on the nosological context make this approach complex and likely difficult to replicate.
Brain MRI is an important tool for neuroprognostics in patients with neurological injuries, and for this reason it is commonly used in clinical practice as part of this multimodal approach.
More specifically, brain MRI with diffusion tensor sequences is a validated prognostic tool in post-anoxic coma and traumatic brain injury, as well as, more recently, in subarachnoid hemorrhage, strokes, and hypoglycemia. However, it has not yet been compared to multimodal neuroprognostics performed by the clinician.
The primary objective is to compare the prognostic performance of two prescribing clinicians with diffusion tensor MRI before and after the MRI scan is performed.
Primary outcome measure: to compare the prognostic performance regarding unfavorable outcomes (Glasgow Outcome Scale Extended \< 5) at 12 months between the two prescribing clinicians and diffusion tensor MRI before and after the MRI scan is performed.
A secondary objective will be, among other things, to study the informational gain provided by MRI in improving clinicians' predictions after receiving the MRI results.
Intensive care clinicians constitute the target population. These are clinicians caring for an intensive care patient with a brain injury who order a brain MRI for prognostic purposes as part of patient care and multimodal neuroprognostics.
On the day of the MRI, two clinicians will complete the research questionnaire assessing the patient's prognosis the day before or a few hours before the MRI (on the same day). Then, as soon as the MRI results are available, the same two clinicians will complete the same questionnaire assessing the patient's prognosis after reviewing the MRI results. Patient data regarding the pathology and prognostic factors will be collected at this time.
Finally, surviving patients will be interviewed at 1 year regarding their independence using the Glasgow Outcome Scale Extended (GOSE) and their quality of life using the Medical Outcomes Study Short Form General Health Survey (SF-12) via a telephone call.
We plan to include 220 patients and approximately 70 clinicians across 8 recruiting centers over a 2-year enrollment period. With a 12-month follow-up period, the total duration of the study will be 3 years.
The statistical analysis will include a description of clinicians' ability to distinguish patient prognosis by measuring the area under the Receiver Operating Characteristic (ROC) curve, or AUC. The prediction concerns an unfavorable outcome, defined as a GOSE score of 1 to 4. Since we had no pre-study data on clinicians' performance in predicting an unfavorable outcome at the time of a prognostic MRI, the inclusion target was set based on data from a previous study at 220 patients, which corresponds to the number of patients we planned to enroll over a 2-year period.
With a mortality rate of over 13% in the neuro-intensive care unit, 86% of which are related to the withdrawal of active treatment, predicting a reliable neurological prognosis is of paramount importance in neuro-intensive care to help clinicians inform family members appropriately and tailor care to the patient's presumed wishes. This allows for the justification of intensive resuscitation treatments in patients with a presumed good prognosis and, conversely, avoids keeping patients with an unfavorable neurological prognosis alive against their presumed wishes.
Current guidelines advocate a multimodal neuroprognostic approach, where the clinician synthesizes prognostic factors from clinical examination, EEG, plasma or CSF biomarkers, and imaging to collaboratively develop an individualized prognosis, even though no study has evaluated the quality of this multimodal prognosis. Furthermore, the existing variability depending on the nosological context makes this approach complex and likely difficult to reproduce. Brain Magnetic Resonance Imaging (MRI) is an important tool for neuroprognostication in patients with neurological injuries, and for this reason, it is commonly used in clinical practice as part of a multimodal approach.
More specifically, brain MRI with diffusion tensor imaging (DTI) sequences is validated prognostic tool in post anoxic coma, traumatic brain injury, and more recently in spontaneous hemorrhagic stroke, subarachnoid hemorrhage, and hypoglycemia. It allows for relatively precise classification of patients after cerebral anoxia or traumatic brain injury into 3 categories: those with an unfavorable outcome (specificity greater than 95%), those with an indeterminate outcome, and those with a favorable outcome (specificity greater than 95%).
It is currently being evaluated in the COMABASE study for its prognostic value in other cerebral pathologies (spontaneous hemorrhagic stroke, subarachnoid aneurysmal hemorrhage, and hypoglycemia).
Despite its excellent discriminatory values (AUC 0.93), it has not been compared to the gold standard, namely multimodal neuroprognosis performed by a panel of clinicians.
The investigators wish to study the informational contribution of MRI with DTI to the clinician's prognostic development. To this end, the investigators will study the degree of prognostic uncertainty experienced by clinicians before DTI scans are performed to determine whether MRI helps reduce this uncertainty.
This research aims to evaluate the prognostic ability of clinicians prescribing diffusion tensor imaging (DTI), specifically the fractional anisotropy and mean diffusivity in the white matter, associated with patient age, and the time between the onset of symptoms and the MRI scan. It also aims to evaluate the predictive power of clinicians integrating multimodal signals (clinical finfings, EEG, and CT scan) regarding neurological prognosis at the time of the MRI scan. The clinicians' predictions will be assessed on the day of the MRI scan and a few hours prior to it, to ensure the closest possible comparison with the prognosis provided by MRI markers.
The investigators need to recruit 220 patients and 70 clinicians across 8 intensives care units in Paris, France.
The planned duration of the research will be 3 years and 2 months, with an inclusion period of 2 years associated with a follow-up period of 14 months (12 months +/- 2 months) in order to include a total of 220 patients.
Detailed protocol:
The investigators will screen every MRI prescribed to establish a prognosis for an intensive care patient.
The day before the MRI scan, the investigators will request the participation in the study of patient's relative and two clinicians from the same Intensive Care Unit (ICU), who are responsible for the patient awaiting prognosis.
If the relatives and the 2 clinicians agree to participate in the study, the 2 clinicians will complete a questionnaire, the day before or the same day, few hours before MRI scan, assessing their knowledge about patient's prognostic factors and allowing them to rate between 0 and 100, the probability of an unfavorable outcome. Note that a clinician may participate in the study for multiple patients.
Then the patient will undergo the MRI scan with DTI. The MRI sequences will contain at minimum, the FLuid Attenuated Inversion Recovery images (FLAIR), Diffusion-Weighted Imaging (DWI), braimstem spectroscopy, Susceptibility-Weighted Imaging (SWI) and Diffusion Tensor Imaging (DTI).
The DTI is aimed to obtain the standardized fractional anisotropy and the standardized mean diffusivity in the 17 regions of white matter defined by the Johns Hopkins Hospital Atlas. Thanks to the fractional anisotropy, the mean diffusivity, the patient age and the time between the brain injury and the MRI scan, the calculator published in Intensive care Medecine (Puybasset et al 2026 PMID : 41782003), will provide the probability of the unfavorable outcome for each patient.
As soon as the MRI results are obtained (on the same day or one day after if possible):
The same 2 clinicians will review the images from MRI and the results from the calculator and will complete once again the questionnaire about prognostic factors and their estimation of the unfavorable outcome.
The investigator will collect data from the patient in intensive care retrospectively as demographic data, the type of brain lesion, the date of the brain lesion, the date sedation was discontinued, the detailed Glasgow Coma Scale score on the day or the day before the MRI scan, eye movement tracking and fluctuations in level of consciousness, duration of ventilation, the limitation of active therapy, the date of discharge from intensive care or the date of death. Others data collections will include the time between the discontinuation of sedation and the MRI scan, the clinician's experience level, and the patient's level of consciousness at the time of the MRI to study their influence on the clinician's prognosis accuracy.
Follow-up of the population at 1 year (+/- 2 months). If the patient is alive and not under legal guardianship, a telephone call will be made to inform the patient and ask for their consent to continue the research.
Then, a Glasgow Outcomes Scale Extended (GOSE) will be administered to the patient or a relative, and a Medical Ouctomes study Short Form General Health Survey (SF-12) will be completed, blinded to the prognostic assessment established by diffusion tensor MRI and the clinicians.
The investigators will analyze clinicians' preMRI prognostic result, clinicians' post MRI prognosic results and the DTI calculator to establish the ROC curve for these 3 prognosis assessments.
Duration of participant participation and duration of the research:
Inclusion period: 2 years Duration of patient participation: maximum 14 months Duration of the research: 3 years and 2 months
The sample size calculation was performed with the secondary objective of comparing clinician prognosis to that of MRI. It was based on the sample size calculation described in the 2024 publication by Jung et al. for comparing two diagnostic tolls using paired data.
The investigators calculated a sample size of 209 patients based on parameters collected from two previously published studies on this topic:
Comparison using the DeLong method for paired studies between the Receiver Operating Characteristic (ROC) curve predicting an unfavorable outcome at 12 months, established by the predictive model based on fractional anisotropy values, mean white matter diffusivity, patient age, and the time between the brain lesion and the mean prediction established by a clinician in charge of the patient the day before the MRI.
This comparison will be performed on all patients and then on patients who survived the intensive care unit.
The agreement between the clinicians' predictions will be studied using intraclass correlation coefficients for paired measures.
All tests were two-sided, and p values \< 0.05 were considered statistically significant.
Patients with missing data on MRI prognostic information clinician-pre-MRI prognosis, or GOSE score at one year will be excluded from the study. These patients will not be replaced, but the investigators are accounting for this loss of of information in the sample size calculation, estimating it at approximately 5%
Intensive care clinicians who care for patients in the intensive care unit with brain injury and who perform brain MRI for prognostic purposes as part of patient care and multimodal neuroprognostics, as well as those patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients :
Exclusion Criteria:
For clinicians - Clinician's refusal to complete the study questionnaires
For patients:
- DTI measurements (anisotropy fraction and mean diffusivity) not feasible before or after treatment
Two clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis. A phone call will be made, blinded to the prognosis made before the MRI and without knowledge of the prognosis established by diffusion tensor MRI, 12 months after the brain injury. This call will be made by a person qualified to administer the questionnaires, in order to obtain a GOSE score.
Clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE <5)
The primary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE \<5). Two clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis. The clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation. "Now that you have all prognostic factors in mind, we would like your estimate of the patient's risk of an unfavorable outcome, on a scale of 0 to 100. This refers to a person who is unable to go shopping or travel independently, and who is unable to live independently, corresponding to a GOSE less than 5, one year after their brain injury." We will use the average of the two prognoses to construct the ROC curve.
Time frame: 1 day before or the day of the MRI and 12 months after the brain injury
Diffusion tensor Imaging's ROC curve for predicting unfavorable patient outcomes at 12 months (Glasgow Outcome Scale Extended (GOSE <5).
Prediction of the risk of unfavourable outcome (GOSE \< 5) by a statistical toll (Support vector machine) published in 2026 (Puybasset et al 2026 PMID : 41782003) using age, time between MRI and brain lesion as well as the mean and normalized value of the fractional anisotropy and mean diffusivity in the 17 regions of white matter defined by the Johns Hopkins Hospital Atlas. As described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.
Time frame: 12 months
Clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE <4).
This secondary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months (Glasgow Outcome Scale Extended (GOSE \<4). Two clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis. The clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation. As described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.
Time frame: 12 months
Clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months after MRI results (Glasgow Outcome Scale Extended (GOSE <5).
This secondary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months just after MRI prediction (the same day) (GOSE \<5). Two clinicians will be interviewed the day after MRI prognosis using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis. The clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation. As described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.
Time frame: 12 months
Clinicians'ROC curve for predicting unfavorable patient outcomes at 12 months after MRI results (Glasgow Outcome Scale Extended (GOSE <4).
This secondary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months just after MRI prediction (the same day) (GOSE \<4). Two clinicians will be interviewed the day after MRI prognosis using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis. The clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation. As described above, the assessment of unfavorable neurological outcomes will be based on the GOSE score.
Time frame: 12 months
Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.
Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 14 months is below that.
Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →